Alliance A051301 (Large B-Cell Lymphoma)

What is the Purpose of this Study?

If you choose to join this study, you will:
- Be randomly assigned (like flipping a coin) to 1 of 2 treatment groups
-- One group will receive the drug ibrutinib
-- The other group will receive placebo (an inactive substance)
What is the Condition Being Studied?
Large B-Cell Lymphoma that has returned after it was getting better

Who Can Participate in this Study?

Adults with Large B-Cell Lymphoma that has relapsed or not responded to treatment.

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to see how a drug called ibrutinib works in your body and against your cancer.

Study Details

Full Title
Alliance A051301: A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Principal Investigator
Jeffrey Crawford
George Barth Geller Distinguished Professor for Research in Cancer

Contacts
Protocol Number
IRB:
PRO00078528

NCT:
NCT02443077
ClinicalTrials.gov
View on ClinicalTrials.gov